Related Experiment Video
Updated: Jun 3, 2026
09:45
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Modulating Alzheimer's disease through caffeine: a putative link to epigenetics.
Sueli Marques1, Vânia L Batalha, Luísa Vaqueiro Lopes
1Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal.
Journal of Alzheimer'S Disease : JAD
|March 24, 2011
Summary
Caffeine may protect against Alzheimer's disease (AD) by blocking adenosine A2A receptors and modulating gene expression. This research explores caffeine's potential epigenetic effects for AD prevention and treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Aging is a primary risk factor for neurodegenerative diseases like Alzheimer's disease (AD).
- Epigenetic modulation of gene expression's role in aging and AD is not fully understood.
- Caffeine, a common stimulant, shows promise in protecting against AD and age-related cognitive decline.
Purpose of the Study:
- To review evidence for caffeine's protective effects in Alzheimer's disease.
- To investigate the role of adenosine A2A receptors and epigenetic modulation in caffeine's action.
- To explore caffeine's potential as an epigenetic modulator for AD therapeutics.
Main Methods:
- Literature review of studies on caffeine, aging, Alzheimer's disease, adenosine A2A receptors, and epigenetics.
- Analysis of data supporting caffeine's mechanism of action in AD.
- Speculative discussion on caffeine's epigenetic modulation capabilities.
Main Results:
- Caffeine's protective effects against AD are linked to blocking adenosine A2A receptors, which are dysregulated in aging and AD.
- Evidence suggests caffeine may influence epigenetic mechanisms relevant to aging and neurodegeneration.
- Adenosine A2A receptor antagonism is a key pathway for caffeine's neuroprotective actions.
Conclusions:
- Caffeine shows potential as a preventive and therapeutic agent for Alzheimer's disease.
- Targeting adenosine A2A receptors and exploring epigenetic modulation are promising avenues for AD intervention.
- Further research into caffeine's epigenetic effects could unlock novel therapeutic strategies for AD.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:46Epigenetic Regulation
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.